Acerta Pharma BV
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.acerta-pharma.com
A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 30
- Registration Number
- NCT05140096
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 72
- Registration Number
- NCT04914936
A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 12
- Registration Number
- NCT04905043
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 59
- Registration Number
- NCT04901923
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 14
- Registration Number
- NCT04898101
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 36
- Registration Number
- NCT04876807
- Locations
- 🇺🇸
Laura Sterling, MD, MPH, Lincoln, Nebraska, United States
A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 18
- Registration Number
- NCT04867941
- Locations
- 🇺🇸
Research Site, Knoxville, Tennessee, United States
A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 48
- Registration Number
- NCT04867980
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 611
- Registration Number
- NCT04529772
- Locations
- 🇺🇦
Research Site, Zaporizhzhia, Ukraine
Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 9
- Registration Number
- NCT04497948
- Locations
- 🇧🇷
Research Site, Sao Paulo, Brazil
© Copyright 2024. All Rights Reserved by MedPath